MTA1—a stress response protein: a master regulator of gene expression and cancer cell behavior

Cancer and Metastasis Reviews

Volumn 33, Issue 4, 2014, Pages 1001-1009

  Wang, Rui An ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Carcinogenesis; Epithelial stem cell misplacement; Hypoxia; Immune stress; Metastasis; MTA1; Stress protein

Indexed keywords

DIMETHYLNITROSAMINE; HEAT SHOCK PROTEIN; METASTASIS ASSOCIATED PROTEIN 1; PROTEIN X; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CARCINOMA CELL; CARCINOMA IN SITU; CELL FUNCTION; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HEAT SHOCK; HEPATITIS B VIRUS; HUMAN; IMMUNITY; INVASIVE CARCINOMA; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION EXPOSURE; STEM CELL MISPLACEMENT THEORY; STROMA; THEORY; UPREGULATION; BIOSYNTHESIS; GENETICS; HEAT SHOCK RESPONSE; IONIZING RADIATION; NEOPLASMS;

CARCINOGENESIS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK RESPONSE; HISTONE DEACETYLASES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; RADIATION, IONIZING; REPRESSOR PROTEINS;

EID: 84914106944     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9525-1     Document Type: Article

References (107)

1. Wang, R. A., Li, Z. S., Zhang, H. Z., Zheng, P. J., Li, Q. L., Shi, J. G., et al. (2013). Invasive cancers are not necessarily from preformed in situ tumours—an alternative way of carcinogenesis from misplaced stem cells. Journal of Cellular and Molecular Medicine, 17, 921–926.
2. Baker, S. G. (2012/2013). Paradox-driven cancer research. Disruptive Science and Technology, 1, 143–148.
3. Soto, A. M., & Sonnenschein, C. (2011). The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays, 33, 332–340.
4. Duesberg, P. (2005). Does aneuploidy or mutation start cancer? Science, 307, 41.
5. Meng, X., Zhong, J., Liu, S., Murray, M., & Gonzalez-Angulo, A. M. (2012). A new hypothesis for the cancer mechanism. Cancer Metastasis Review, 31, 247–268.
6. Weinberg, R. A. (2014). Coming full circle-from endless complexity to simplicity and back again. Cell, 157, 267–271.
7. Turkalp, Z., Karamchandani, J., & Das, S. (2014). IDH Mutation in. Glioma: New insights and promises for the future. JAMA Neurology. doi:10.1001/jamaneurol.2014.1205.
8. Gorovets, D., Kannan, K., Shen, R., Kastenhuber, E. R., Islamdoust, N., Campos, C., et al. (2012). IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clinical Cancer Research, 18, 2490–2501.
9. Qi, S. T., Yu, L., Lu, Y. T., Ou, Y. H., Li, Z. Y., Wu, L. X., et al. (2011). IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas. Oncology Reports, 26, 1479–1485.
10. Hong, J. W., Lee, S., Kim, D. C., Kim, K. H., & Song, K. H. (2014). Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Annals of Dermatology, 26, 195–202.
11. Broders, A. C. (1932). Carcinoma in situ contrasted with benign penetrating epithelium. JAMA-Journal of The American Medical Association, 99, 1670–1674.
12. Burstein, H. J., Polyak, K., Wong, J. S., Lester, S. C., & Kaelin, C. M. (2004). Ductal carcinoma in situ of the breast. New England Journal of Medicine, 350, 1430–1441.
13. Latta, E. K., Tjan, S., Parkes, R. K., & O’Malley, F. P. (2002). The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Modern Pathology, 15, 1318–1325.
14. Barnes, D. M., Bartkova, J., Camplejohn, R. S., Gullick, W. J., Smith, P. J., & Millis, R. R. (1992). Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? European Journal of Cancer, 28, 644–648.
15. Allred, D. C., Clark, G. M., Molina, R., Tandon, A. K., Schnitt, S. J., Gilchrist, K. W., et al. (1992). Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathology, 23, 974–979.
16. Frykberg, E. R. (1999). Lobular carcinoma in situ of the breast. Breast Journal, 5, 296–303.
17. Sanders, M. E., Schuyler, P. A., Dupont, W. D., & Page, D. L. (2005). The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer, 103, 2481–2484.
18. Virnig, B. A., Wang, S. Y., Shamilyan, T., Kane, R. L., & Tuttle, T. M. (2010). Ductal carcinoma in situ: risk factors and impact of screening. Journal of National Cancer Institute Monographs, 2010, 113–116.
19. Wang, R. A., Li, Z. S., Yan, Q. G., Bian, X. W., Ding, Y. Q., Du, X., et al. (2014). Resistance to apoptosis should not be taken as a hallmark of cancer. Chinese Journal of Cancer, 33, 47–50.
20. Baker, S. G. (2012). Paradoxes in carcinogenesis should spur new avenues of research: an historical perspective. Disruptive Sciences and Technology., 1, 100–107.
21. Miller, F. R., Santner, S. J., Tait, L., & Dawson, P. J. (2000). MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. Journal of National Cancer Institute, 92, 1185–1186.
22. Wang, R. A., Li, Q. L., Li, Z. S., Zheng, P. J., Zhang, H. Z., Huang, X. F., et al. (2013). Apoptosis drives cancer cells proliferate and metastasize. Journal of Cellular and Molecular Medecine, 17, 205–211.
23. Lipponen, P., Aaltomaa, S., Kosma, V. M., & Syrjanen, K. (1994). Apoptosis in breast cancer as related to histopathological characteristics and prognosis. European Journal of Cancer, 30A, 2068–2073.
24. Lipponen, P. K., & Aaltomaa, S. (1994). Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. Journal of Pathology, 173, 333–339.
25. Zhang, G. J., Kimijima, I., Abe, R., Watanabe, T., Kanno, M., Hara, K., et al. (1998). Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Research, 18, 1989–1998.
26. Sinicrope, F. A., Hart, J., Hsu, H. A., Lemoine, M., Michelassi, F., & Stephens, L. C. (1999). Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clinical Cancer Research, 5, 1793–1804.
27. Lipponen, P. (1999). Apoptosis in breast cancer: relationship with other pathological parameters. Endocrine Related Cancer, 6, 13–16.
28. Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Matsuoka, Y., et al. (1999). Apoptosis in breast cancer and its relationship to clinicopathological characteristics and prognosis. Journal of Surgical Oncology, 71, 226–234.
29. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.
30. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.
31. Kuo, C. Y., Tsai, J. I., Chou, T. Y., Hung, M. J., Wu, C. C., Hsu, S. L., et al. (2012). Apoptosis induced by hepatitis B virus X protein in a CCL13-HBx stable cell line. Oncology Reports, 28, 127–132.
32. Tang, R. X., Kong, F. Y., Fan, B. F., Liu, X. M., You, H. J., Zhang, P., et al. (2012). HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module. World Journal of Gastroenterology, 18, 1485–1495.
33. Hu, L., Chen, L., Yang, G., Li, L., Sun, H., Chang, Y., et al. (2011). HBx sensitizes cells to oxidative stress-induced apoptosis by accelerating the loss of Mcl-1 protein via caspase-3 cascade. Molecular Cancer, 10, 43.
34. Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Choi, K. H., Yu, D. Y., et al. (2010). HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. Journal of Molecular Biology, 397, 917–931.
35. Cheng, P., Li, Y., Yang, L., Wen, Y., Shi, W., Mao, Y., et al. (2009). Hepatitis B virus X protein (HBx) induces G2/M arrest and apoptosis through sustained activation of cyclin B1-CDK1 kinase. Oncology Reports, 22, 1101–1107.
36. Niu, D., Zhang, J., Ren, Y., Feng, H., & Chen, W. N. (2009). HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 cells. Molecular Oncology, 3, 67–76.
37. Tanaka, Y., Kanai, F., Kawakami, T., Tateishi, K., Ijichi, H., Kawabe, T., et al. (2004). Interaction of the hepatitis B virus X protein (HBx) with heat shock protein 60 enhances HBx-mediated apoptosis. Biochemical and Biophysical Research Communication, 318, 461–469.
38. Su, F., Theodosis, C. N., & Schneider, R. J. (2001). Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. Journal of Virology, 75, 215–225.
39. Chen, L., Park, S. M., Tumanov, A. V., Hau, A., Sawada, K., Feig, C., et al. (2010). CD95 promotes tumour growth. Nature, 465, 492–496.
40. Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F. F., et al. (2011). Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine, 17, 860–866.
41. Sun, K., Guo, X. L., Zhao, Q. D., Jing, Y. Y., Kou, X. R., Xie, X. Q., et al. (2013). Paradoxical role of autophagy in the dysplastic and tumor-forming stages of hepatocarcinoma development in rats. Cell Death and Disease, 4, e501.
42. Murphy, K. L., Kittrell, F. S., Gay, J. P., Jager, R., Medina, D., & Rosen, J. M. (1999). Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene, 18, 6597–6604.
43. Knowlton, K., Mancini, M., Creason, S., Morales, C., Hockenbery, D., & Anderson, B. O. (1998). Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. Journal of Surgical Research, 76, 22–26.
44. de La Coste, A., Mignon, A., Fabre, M., Gilbert, E., Porteu, A., Van Dyke, T., et al. (1999). Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Research, 59, 5017–5022.
45. Yang, Q., Sakurai, T., Yoshimura, G., Suzuma, T., Umemura, T., Nakamura, M., et al. (2003). Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncology Reports, 10, 121–125.
46. Callagy, G. M., Pharoah, P. D., Pinder, S. E., Hsu, F. D., Nielsen, T. O., Ragaz, J., et al. (2006). Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical Cancer Research, 12, 2468–2475.
47. Lee, K. H., Im, S. A., Oh, D. Y., Lee, S. H., Chie, E. K., Han, W., et al. (2007). Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer, 7, 63.
48. Rolland, P., Spendlove, I., Madjd, Z., Rakha, E. A., Patel, P., Ellis, I. O., et al. (2007). The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. International Journal of Cancer, 120, 1311–1317.
49. Poincloux, L., Durando, X., Seitz, J. F., Thivat, E., Bardou, V. J., Giovannini, M. H., et al. (2009). Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surgical Oncology-Oxford, 18, 357–365.
50. Watson, N. F., Madjd, Z., Scrimegour, D., Spendlove, I., Ellis, I. O., Scholefield, J. H., et al. (2005). Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World Journal of Surgical Oncology, 3, 47.
51. Tomita, M., Matsuzaki, Y., Edagawa, M., Shimizu, T., Hara, M., & Onitsuka, T. (2003). Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. European Journal of Surgical Oncology, 29, 654–657.
52. Yang, C., Davis, J. L., Zeng, R., Vora, P., Su, X., Collins, L. I., et al. (2013). Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discovery, 3, 212–223.
53. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15, 232–239.
54. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15, 220–231.
55. Bouchard, G., Bouvette, G., Therriault, H., Bujold, R., Saucier, C., & Paquette, B. (2013). Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. British Journal of Cancer, 109, 1829–1838.
56. Pani, G., Galeotti, T., & Chiarugi, P. (2010). Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Review, 29, 351–378.
57. Prehn, R. T., & Main, J. M. (1957). Immunity to methylcholanthrene-induced sarcomas. Journal National Cancer Institute, 18, 769–778.
58. Wang, R. A., & Yan, Q. G. (2013). Adaptation biology and medicine (pp. 129–136). New Delhi: Narosa Publishing House.
59. Cairns, J. (1980). Efficiency of the adaptive response of Escherichia coli to alkylating agents. Nature, 286, 176–178.
60. Wu, J., Rosenbaum, E., Begum, S., & Westra, W. H. (2007). Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis. American Journal of Dermatopathology, 29, 534–537.
61. Baserga, R. (1965). The relationship of the cell cycle to tumor growth and control of cell division: a review. Cancer Research, 25, 581–595.
62. Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269, 22958–22963.
63. Toh, Y., Oki, E., Oda, S., Tokunaga, E., Ohno, S., Maehara, Y., et al. (1997). Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. International Journal of Cancer, 74, 459–463.
64. Toh, Y., Kuwano, H., Mori, M., Nicolson, G. L., & Sugimachi, K. (1999). Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. British Journal of Cancer, 79, 1723–1726.
65. Liang, Y., Dong, Y., Zhao, J., & Li, W. (2013). YES1 activation elicited by heat stress is anti-apoptotic in mouse pachytene spermatocytes. Biology of Reproduction, 89, 131.
66. Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, R. D., Xia, W., Hung, M. C., Sarin, S. K., et al. (2010). NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene, 29, 1179–1189.
67. Li, W., Wu, Z. Q., Zhao, J., Guo, S. J., Li, Z., Feng, X., et al. (2011). Transient protection from heat-stress induced apoptotic stimulation by metastasis-associated protein 1 in pachytene spermatocytes. PLoS One, 6, e26013.
68. Li, W., Bao, W., Ma, J., Liu, X., Xu, R., Wang, R. A., et al. (2008). Metastasis tumor antigen 1 is involved in the resistance to heat stress-induced testicular apoptosis. FEBS Letters, 582, 869–873.
69. Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25, 1231–1241.
70. Ohshiro, K., Reddy, S. D., Pakala, S. B., Lee, M. H., Zhang, Y., et al. (2009). E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proceedings of the National Academy of Sciences of USA, 106, 17493–17498.
71. Li, D. Q., Divijendra, N. R. S., Pakala, S. B., Wu, X., Zhang, Y., Rayala, S. K., et al. (2009). MTA1 coregulator regulates p53 stability and function. Journal of Biological Chemistry, 284, 34545–34552.
72. Li, D. Q., Ohshiro, K., Khan, M. N., & Kumar, R. (2010). Requirement of MTA1 in ATR-mediated DNA damage checkpoint function. Journal of Biological Chemistry, 285, 19802–19812.
73. Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285, 23590–23597.
74. Mazumdar, A., Wang, R. A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3, 30–37.
75. Motavaf, M., Safari, S., Saffari, J. M., & Alavian, S. M. (2013). Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virologica, 57, 389–396.
76. Yoo, Y. G., Na, T. Y., Seo, H. W., Seong, J. K., Park, C. K., Shin, Y. K., et al. (2008). Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. Oncogene, 27, 3405–3413.
77. Xin, B., Wang, X. Y., Li, Y., Qin, J. H., Ma, X. J., Yin, J. P., et al. (2012). Expression and potential role of metastasis-associated protein 1 in the induced carcinogenesis of mouse liver. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi(Chinese), 28, 801–803.
78. Hofer, M. D., Tapia, C., Browne, T. J., Mirlacher, M., Sauter, G., & Rubin, M. A. (2006). Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Archives of Pathology and Laboratory Medicine, 130, 989–996.
79. Luo, H., Li, H., Yao, N., Hu, L., & He, T. (2014). Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies. Tumour Biology, 35, 5823–5832.
80. Jang, K. S., Paik, S. S., Chung, H., Oh, Y. H., & Kong, G. (2006). MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Science, 97, 374–379.
81. Zhang, H., Stephens, L. C., & Kumar, R. (2006). Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clinical Cancer Research, 12, 1479–1486.
82. Martin, M. D., Hilsenbeck, S. G., Mohsin, S. K., Hopp, T. A., Clark, G. M., Osborne, C. K., et al. (2006). Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Research and Treatment, 95, 7–12.
83. Cheng, C. W., Liu, Y. F., Yu, J. C., Wang, H. W., Ding, S. L., Hsiung, C. N., et al. (2012). Prognostic significance of cyclin D1, beta-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast. Annals of Surgical Oncology, 19, 4129–4139.
84. Higashijima, J., Kurita, N., Miyatani, T., Yoshikawa, K., Morimoto, S., Nishioka, M., et al. (2011). Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer. Oncology Reports, 26, 343–348.
85. Li, S. H., Wang, Z., & Liu, X. Y. (2009). Metastasis-associated protein 1 (MTA1) overexpression is closely associated with shorter disease-free interval after complete resection of histologically node-negative esophageal cancer. World Journal of Surgery, 33, 1876–1881.
86. Sasaki, H., Moriyama, S., Nakashima, Y., Kobayashi, Y., Yukiue, H., Kaji, M., et al. (2002). Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer, 35, 149–154.
87. Xu, L., Mao, X. Y., Fan, C. F., & Zheng, H. C. (2011). MTA1 expression correlates significantly with cigarette smoke in non-small cell lung cancer. Virchows Archiv: an International Journal of Pathology, 459, 415–422.
88. Hamatsu, T., Rikimaru, T., Yamashita, Y., Aishima, S., Tanaka, S., Shirabe, K., et al. (2003). The role of MTA1 gene expression in human hepatocellular carcinoma. Oncology Reports, 10, 599–604.
89. Moon, W. S., Chang, K., & Tarnawski, A. S. (2004). Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Human Pathology, 35, 424–429.
90. Sasaki, H., Yukiue, H., Kobayashi, Y., Nakashima, Y., Kaji, M., Fukai, I., et al. (2001). Expression of the MTA1 mRNA in thymoma patients. Cancer Letters, 174, 159–163.
91. Murakami, M., Kaul, R., & Robertson, E. S. (2008). MTA1 expression is linked to ovarian cancer. Cancer Biology & Therapy, 7, 1468–1470.
92. Prisco, M. G., Zannoni, G. F., De Stefano, I., Vellone, V. G., Tortorella, L., Fagotti, A., et al. (2012). Prognostic role of metastasis tumor antigen 1 in patients with ovarian cancer: a clinical study. Human Pathology, 43, 282–288.
93. Deng, Y. F., Zhou, D. N., Ye, C. S., Zeng, L., & Yin, P. (2012). Aberrant expression levels of MTA1 and RECK in nasopharyngeal carcinoma: association with metastasis, recurrence, and prognosis. The Annals of Otology, Rhinology and Laryngology, 121, 457–465.
94. Song, L., Wang, Z., & Liu, X. (2013). MTA1: a prognosis indicator of postoperative patients with esophageal carcinoma. The Thoracic and Cardiovascular Surgeons, 61, 479–485.
95. Iguchi, H., Imura, G., Toh, Y., & Ogata, Y. (2000). Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. International Journal of Oncology, 16, 1211–1214.
96. Hofer, M. D., Chang, M. C., Hirko, K. A., Rubin, M. A., & Nose, V. (2009). Immunohistochemical and clinicopathological correlation of the metastasis-associated gene 1 (MTA1) expression in benign and malignant pancreatic endocrine tumors. Modern Pathology, 22, 933–939.
97. Hofer, M. D., Kuefer, R., Varambally, S., Li, H., Ma, J., Shapiro, G. I., et al. (2004). The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Research, 64, 825–829.
98. Dias, S. J., Zhou, X., Ivanovic, M., Gailey, M. P., Dhar, S., Zhang, L., et al. (2013). Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans. Scientific Report, 3, 2331.
99. Bruning, A., Makovitzky, J., Gingelmaier, A., Friese, K., & Mylonas, I. (2009). The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells. Histochemistry and Cell Biology, 132, 33–38.
100. Manavathi, B., Peng, S., Rayala, S. K., Talukder, A. H., Wang, M. H., Wang, R. A., et al. (2007). Repression of Six3 by a corepressor regulates rhodopsin expression. Proceedings of the National Academy of Sciences of the United States of America, 104, 13128–13133.
101. Kumar, R., Balasenthil, S., Manavathi, B., Rayala, S. K., & Pakala, S. B. (2010). Metastasis-associated protein 1 and its short form variant stimulates Wnt1 transcription through promoting its derepression from Six3 corepressor. Cancer Research, 70, 6649–6658.
102. Pakala, S. B., Singh, K., Reddy, S. D., Ohshiro, K., Li, D. Q., Mishra, L., et al. (2011). TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30, 2230–2241.
103. Moon, H. E., Cheon, H., & Lee, M. S. (2007). Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncology Reports, 18, 1311–1314.
104. Choubey, D. (2000). P202: an interferon-inducible negative regulator of cell growth. Journal of Biological Regulators and Homeostatic Agents, 14, 187–192.
105. Yan, D. H., Wen, Y., Spohn, B., Choubey, D., Gutterman, J. U., & Hung, M. C. (1999). Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. Oncogene, 18, 807–811.
106. Li, D. Q., Pakala, S. B., Reddy, S. D., Peng, S., Balasenthil, S., Deng, C. X., et al. (2013). Metastasis-associated protein 1 is an integral component of the circadian molecular machinery. Nature Communications, 4, 2545.
107. Pakala, S. B., Rayala, S. K., Wang, R. A., Ohshiro, K., Mudvari, P., Reddy, S. D., et al. (2013). MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer. Cancer Research, 73, 3761–3770.